Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1293-1302

  Kienzler, J L ^a   Queille Roussel, C ^b   Mugglestone, C ^c   Ortonne, J P ^d   Larnier, C ^a  

^a Department of Clinical Pharmacology   (Switzerland)

^b Centre de Pharmacologie Clinique Applique a la Dermatologie   (France)

^c BIBRA INTERNATIONAL   (United Kingdom)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Anti fungal drug; Dermatophytoses; Pharmacokinetics; Single topical dose; Stratum corneum; Terbinafine

Indexed keywords

ACRYLIC ACID DERIVATIVE; ALCOHOL; COPOLYMER; FILM FORMING SOLUTION; OCTYLACRYLAMIDE COPOLYMER; TERBINAFINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; BACK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN; STANDARD; STRATUM CORNEUM;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; DERMATOMYCOSES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NAPHTHALENES; OINTMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN;

EID: 34347247270     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199664     Document Type: Conference Paper

References (14)

1. Evans EG: Tinea pedis: clinical experience and efficacy of short treatment. Dermatology 1997;194(Suppl 1):3-6
2. Korting HC, Rychlik R, Pfeil B. Treatment of interdigital tinea pedis: a systematic review. Dtsch Med Wochensch 2003;128:1819-24
3. Meinhof W, Girardi RM, Stracke A. Patient non-compliance in dermatomycosis: results of a survey among dermatologists, general practitioners and patients. Dermatologica 1984;169(Suppl 1):57-66
4. Korting HC, Tietz H-J, Bräutigam M, et al. One week terbinafine 1% cream (Lamisil®) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycol 2001;39:335-40
5. Ryder NS , Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997;8:275-87
6. Hill S, Thomas R, Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil®) 1% cream. Br J Dermatol 1992;127:396-400
7. Alberti I, Kalia YN, Naik A, et al. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res 2001;18:1472-5
8. Topical dermatological drug product NDAs and ANDAs - in vivo bioavailability, bioequivalence, in vitro release and associated studies. United States Food and Drug Administration; June 1998
9. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-54
10. Strober BE, Washenik K, Schupak JL. Principles of topical therapy. In: Burns T, Breathnatch S, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology, 7th edn. Oxford: Blackwell Science, 2004:2319-23
11. Alberti I, Kalia YN, Naik A, et al. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 2001;219:11-19
12. Weinstein GD, Van Scott EJ. Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965;45:257-62
13. Nakashima T, Nozawa A, Majima T. A novel method using micropig stratum corneum in vitro for the evaluation of anti-Trichophyton mentagrophytes activity. Microbiol Immunol 2002;46:521-5
14. Ortonne JP, Korting HC, Viguie-Vallanet C, et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomised, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2006;20:1307-13